

Meeting Minutes: Drug Formulary Committee

Date & Time: January 9, 2020; 5:30-9 PM
Minutes prepared by: Hind Douiki and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., PhD.; Monica Brands, RPh.; Al Heaton, RPh; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; Kelly Ruby, PharmD.; Michael Sprehe, MD; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.; Ramona Powell, PharmD.
- Members absent: Stacey Ness, PharmD.; James Phillips, MD.
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.
- Others in attendance: Hind Douiki, PharmD.; Ariane Casey, PharmD.

Report of the Chair

- Dr. Ness was absent; Mr. Williams presided over the meeting.

Approval of Minutes

- Minutes from the November 2019 meeting were reviewed and approved.

DHS Housekeeping

- Mr. Williams made a motion to recommend that DHS not send written comments to committee members or not consider verbal comments delivered at DFC meetings if they are incomplete (i.e., if the completed conflict of interest disclosure form is not accompanying the written or verbal comment). The motion carried by unanimous vote. Chad Hope will consult with DHS' counsel and report back at a future meeting.

Old Business – None

New Business

New Specialty Drugs for Continued PA

- The committee discussed Baqsimi and recommended to the department by a unanimous vote that Baqsimi remain on PA.

- The committee discussed Gvoke and recommended to the department by a unanimous vote that Gvoke remain on PA.
- The committee discussed Rozlytrek and recommended to the department by a unanimous vote that Rozlytrek remain on PA, with the addition of “If this is not possible, Rozlytrek dose will be decreased” to the last bullet of the “Initial Approval Criteria”.
- The committee discussed Inrebic and recommended to the department by a unanimous vote that Inrebic remain on PA with the following revisions to the criteria:
 - Delete the second sub-bullet of the 6th bullet of the “Initial approval criteria”, and add a bullet that states the following: “Patient will avoid concomitant use with dual CYP3A4 and CYP2C19 inhibitors (e.g., ketoconazole, etc.). If this is not possible, Inrebic dose will be decreased”.
- The committee discussed Rinvoq and recommended to the department by a unanimous vote that Rinvoq be a tier 2 nonpreferred product in the Immunomodulators drug class.
- The committee discussed Nayzilam and recommended to the department by a majority vote that Nayzilam remain on PA with replacing the second sub-bullet to “Patient has a diagnosis of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern”. The committee also recommended to the department by a majority vote that Nayzilam be nonpreferred in the PDL and that it be placed in a separate drug class, which will be named “Anticonvulsants, Other”. This class will include Nayzilam (Nasal) and Diastat (Rectal) at this time.

Preferred Drug List Review

- The committee discussed the Acne Agents, Topical therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Acne Agents, Topical drugs remain as presented.
- The committee discussed the Alzheimer’s Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Alzheimer’s Agents drugs remain as presented.
- The committee discussed the Androgenic Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Androgenic Agents drugs remain as presented.
- The committee discussed the Angiotensin Modulator Combinations therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Angiotensin Modulator Combinations drugs remain as presented.

- The committee discussed the Angiotensin Modulator therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Angiotensin Modulator drugs remain as presented.
- The committee discussed the Antibiotics, Inhaled therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antibiotics, Inhaled drugs remain as presented.
- The committee discussed the Antibiotics, Topical therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antibiotics, Topical drugs remain as presented.
- The committee discussed the Anticoagulants therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Anticoagulants drugs remain as presented.
- The committee discussed the Anticonvulsants therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Anticonvulsants drugs remain as presented except for the changes recommended during the discussion of Nayzilam.
- The committee discussed the Antidepressants, Other therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antidepressants, Other drugs remain as presented.
- The committee discussed the Antidepressants, SSRIs therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antidepressants, SSRIs drugs remain as presented.
- The committee discussed the Antiemetic/Antivertigo Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antiemetic/Antivertigo Agents drugs remain as presented.
- The committee discussed the Antifungals, Oral therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antifungals, Oral drugs remain as presented.
- The committee discussed the Antihistamines, Minimally Sedating therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antihistamines, Minimally Sedating drugs remain as presented.
- The committee discussed the Antimigraine Agents, Other therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antimigraine Agents, Other drugs remain as presented.
- The committee discussed the Antimigraine Agents, Triptans therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antimigraine Agents, Triptans drugs remain as presented.

- The committee discussed the Antiparasitics, Topical therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antiparasitics, Topical drugs remain as presented.
- The committee discussed the Antiparkinson's Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antiparkinson's Agents drugs remain as presented.
- The committee discussed the Diabetes Meters, Continuous class and recommended to the department by a majority vote that the preferred and non-preferred Diabetes Meters, Continuous products remain as presented.
- The committee discussed the Transmitters and Sensors class and recommended to the department by a majority vote that the preferred and non-preferred Transmitters and Sensors products remain as presented.
- The committee also recommended to the department by a majority vote that products under Diabetes Meters, Continuous PDL class and Transmitter and Sensors PDL class be managed under the pharmacy benefit.

Adjournment

- The meeting was adjourned at approximately 8:55 PM Central Time.